Millennium Management
ARTV

Millennium Management’s Artiva Biotherapeutics ARTV Stock Holding History

Millennium Management’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$794K Sell
123,270
-93,827
-43% -$464K ﹤0.01% 4539
2025
Q4 		$931K Sell
217,097
-45,063
-17% -$170K ﹤0.01% 4535
2025
Q3 		$752K Sell
262,160
-64,907
-20% -$174K ﹤0.01% 4830
2025
Q2 		$494K Buy
+327,067
New +$687K ﹤0.01% 4923

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Millennium Management's ARTV Position: Q1 2026 in Review

Millennium Management reduced its Artiva Biotherapeutics (ARTV) stake by 43% in Q1 2026, selling an estimated $464K and leaving 123,270 shares worth $794K. The position accounts for ﹤0.01% of the portfolio, ranked #4539.

Millennium Management first reported a position in ARTV in Q2 2025 and has held it in 4 quarters since. The position peaked at $931K in Q4 2025. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

  • Millennium Management held 123,270 shares of Artiva Biotherapeutics worth $794K as of Q1 2026.
  • Millennium Management sold 93,827 Artiva Biotherapeutics shares in Q1 2026, an estimated $464K.
  • Artiva Biotherapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #4539 holding.
  • Millennium Management first reported a position in Artiva Biotherapeutics in Q2 2025 and has held it in 4 quarters since.
  • Millennium Management's Artiva Biotherapeutics position peaked at $931K in Q4 2025.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.